Search Results
Your search for ,USE matches 11258 pages
Showing 451 - 500Patterns in Oncology Drug Use After Accelerated Approval Is Withdrawn
The accelerated approval program of the U.S. Food and Drug Administration (FDA) allows certain medications to be marketed if they are indicated for serious disease and there has been preliminary evidence of the drug’s efficacy. Pharmaceutical companies must then conduct postapproval trials to...
Breast Cancer Radiotherapy: 1- vs 3-Week Course
A 1-week course of postsurgery radiotherapy demonstrated comparable safety and efficacy to the traditional 3-week regimen in patients with early-stage breast cancer, according to new findings presented by Brunt et al at the European Society for Radiotherapy and Oncology (ESTRO) 2025 Annual Meeting...
Ablative Radiation Therapy for Resectable Pancreatic Ductal Adenocarcinoma
Ablative radiation therapy is considered to be an alternative to surgery, providing an effective noninvasive option for local treatment of many types of cancer, but it is unknown whether ablative radiation therapy is effective for pancreatic ductal adenocarcinoma. Surgery provides improved...
Rakesh K. Jain, PhD, FAACR, Honored With 2025 AACR Award for Lifetime Achievement in Cancer Research
The 2025 AACR Award for Lifetime Achievement in Cancer Research was presented to Rakesh K. Jain, PhD, FAACR, during the 2025 American Association for Cancer Research (AACR) Annual Meeting in Chicago. This award honors individuals who have made significant fundamental contributions to cancer...
Joint Clinical Practice Guideline Addresses Opioid Conversion for Patients With Cancer
Several medical organizations recently released a joint Clinical Practice Guideline to provide recommendations on opioid conversion in adults with cancer.1 ASCO, together with the Multinational Association of Supportive Care in Cancer (MASCC), American Academy of Hospice and Palliative Medicine,...
Evolving Role of Surgical De-escalation for Endometrial, Ovarian, Cervical, and Vulvar Cancers
For more than a decade, the field of gynecologic oncology has witnessed a movement toward surgical de-escalation through the increased use of minimally invasive surgical techniques and sentinel lymph node techniques. At the 2025 Society of Gynecologic Oncology (SGO) Annual Meeting on Women’s...
Quick Takes on Research Findings on Novel Therapies for Gynecologic Cancers
The 2025 Society of Gynecologic Oncology (SGO) Annual Meeting on Women’s Cancer advanced the field with updates of practice-changing trials and other research that challenges the conventional approaches to treating gynecologic cancers. We have briefly captured some of that research here for readers ...
Everolimus Plus Lanreotide vs Everolimus Alone in Aggressive Gastroenteropancreatic Neuroendocrine Tumors
In patients with aggressive gastroenteropancreatic neuroendocrine tumors, first-line treatment with the mTOR inhibitor everolimus and the somatostatin analog lanreotide more than doubled the median progression-free survival for patients vs everolimus alone, in the phase III JCOG1901 (STARTER-NET)...
Symptoms Preceding Unplanned Acute Care in Patients With Cancer
In a single-institution cohort study reported in JAMA Network Open, Chang et al identified patterns of symptoms preceding unplanned acute care encounters for patients with cancer. Study Details The study involved data from all unplanned acute care encounters (emergency department visits and...
Molecular Profiling May Optimize Treatment for Endometrial Cancer
A major international study, PORTEC-4a, provides evidence that molecular profiling may safely reduce the need for radiotherapy in some women with early-stage endometrial cancer while identifying those who would benefit from more intensive treatment. The results, presented at ESTRO 2025, may mark a...
New Treatment Approach Could Enhance Care for Aggressive Relapsed/Refractory T- and NK-Cell Lymphomas
Investigators have uncovered how a specific sequence of cancer therapies could improve outcomes among patients with relapsed/refractory mature T- and natural killer (NK)-cell lymphomas, according to a recent study published by Sorial et al in the British Journal of Haematology. Background...
Cancer Briefs From Digestive Disease Week 2025
Cancer-related studies were among the nearly 6,000 abstracts presented at Digestive Disease Week® (DDW) 2025, including research on artificial intelligence (AI) in patient communication, polyp detection, and colonoscopy prep. Use of AI in Patient Communication AI outperformed physicians in...
Early-Stage Stomach Cancer Diagnoses on the Rise
Stomach cancers are increasingly being diagnosed at less advanced, more treatable stages—a shift that marks major progress in detecting one of the deadliest forms of cancer, according to a study presented at Digestive Disease Week® (DDW) 2025 (Abstract Sa1374). “These trends suggest that...
Addition of Perioperative Pembrolizumab to Standard of Care in Newly Diagnosed Locally Advanced Head and Neck Cancer
In the phase III KEYNOTE-689 trial, perioperative use of the PD-1 inhibitor pembrolizumab given with standard therapy significantly improved event-free survival in newly diagnosed, previously untreated patients with locally advanced head and neck squamous cell carcinoma, researchers reported at the ...
Use of CAD/CAM May Improve Jaw Reconstruction Outcomes Among Patients With Head and Neck Cancer
The use of computer-aided design and manufacturing (CAD/CAM) techniques for planning jaw reconstructions for patients with head and neck cancer undergoing free fibula reconstruction of the lower jaw may potentially shorten the duration of the surgery and reduce removal rates due to complications,...
Adavosertib in Recurrent or Persistent Uterine Serous Carcinoma
In the phase IIb ADAGIO trial, reported in the Journal of Clinical Oncology, Liu et al found that the Wee1 inhibitor adavosertib showed some activity in patients with recurrent or persistent uterine serous carcinoma. However, its use was associated with high toxicity rates. Study Details In the...
Use of Ruxolitinib to Resolve Ciltacabtagene Autoleucel–Induced Parkinsonism in Patients With Multiple Myeloma
Ruxolitinib may prove to be an effective treatment of parkinsonism arising from ciltacabtagene autoleucel treatment for patients with multiple myeloma, according to the results of a case report published in the Journal of Hematology. The report featured two cases of patients with multiple myeloma...
Cannabis Use Disorder Significantly Increases Mortality Risk in Colorectal Cancer
Patients with colorectal cancer and a history of cannabis use disorder had a more than 20 times higher risk of mortality within 5 years than those without cannabis use order, according to the results of a study published in Annals of Epidemiology. The 5-year mortality rate in patients with a...
2025 ACS Cancer Prevention, Early Detection Report: Cancer Screening Rates, Modifiable Risk Factors
Investigators have uncovered mixed progress in major cancer risk factors, preventive behaviors, and screenings in the post–COVID-19 pandemic period among adults in the United States, according to a new study published by Bandi et al in Cancer Epidemiology, Biomarkers & Prevention. Background An ...
DDW 2025: Genetic Mutations Linked to Worse Stomach Cancer Outcomes
Using next-generation DNA sequencing, researchers have identified four specific genes whose mutations are linked to the development and progression of lethal stomach cancers. This could potentially enable practitioners to offer targeted treatments that would spare many patients from unnecessarily...
AACR 2025: Using Single-Cell RNA Sequencing to Evaluate Cell States in AML
A new gene-expression atlas developed using single-cell RNA sequencing data sheds light on how normal hematopoietic cells differentiate and was used to catalog the multiple ways aberrant differentiation can lead to acute myeloid leukemia (AML). Andy G.X. Zeng, PhD, an MD/PhD candidate at the...
AACR 2025: AI-Driven Analysis of Digital Pathology Images May Improve Sarcoma Subtyping Among Pediatric Patients
A novel artificial intelligence (AI)-based model could accurately classify sarcomas among pediatric patients using digital pathology images alone, according to new findings presented by Thiesen et al at the 2025 American Association for Cancer Research (AACR) Annual Meeting (Abstract 2423/8)....
AACR 2025: AI-Driven Model For Identifying Cancer Cachexia
Use of a multimodal deep learning–based model led to more accurate and earlier identifications of cancer cachexia than standard clinical and radiological observations, according to findings presented at the 2025 American Association for Cancer Research (AACR) Annual Meeting (Abstract 1143)....
AACR 2025: Pretrained AI Models Could Help Accurately Diagnose Nonmelanoma Skin Cancers in Resource-Limited Settings
Artificial intelligence (AI) models pretrained on vast data sets may outperform standard baseline models in identifying nonmelanoma skin cancers from digital images of tissue samples, according to new findings presented by Song et al at the 2025 American Association for Cancer Research (AACR)...
AACR 2025: Survival Outcomes May Improve When Treatment Is Guided by Using Both Tissue and Liquid Biopsies
Although next-generation sequencing to assist decision-making for genomics-driven therapy in patients with advanced solid tumors has traditionally been conducted using tissue biopsy samples, recent data support the use of plasma-based circulating tumor DNA (ctDNA) for the genomic profiling of solid ...
AACR 2025: Use of ctDNA-Based Liquid Biopsy Assay in Resectable Colorectal Cancer
Interim results from the VICTORI study showed that an ultrasensitive circulating tumor DNA (ctDNA)-based liquid biopsy assay was effective in detecting signs of cancer recurrence prior to imaging and provided prognostic value within 1 month after surgery in patients with colorectal cancer. The...
AACR 2025: Nonoperative Management of Mismatch Repair–Deficient Tumors
PD-1 blockade with the PD-1 inhibitor dostarlimab-gxly induced complete tumor clearance and resolved the need for surgery in patients with locally advanced, mismatch repair–deficient (dMMR) cancers, according to preliminary results from a phase II trial presented at the 2025 American Association...
Childhood Exposure to Bacterial Toxin May Trigger Early-Onset Colorectal Cancer
Researchers may have identified the bacterial toxin colibactin as a potential factor contributing to the concerning rise in early-onset colorectal cancer, according to a novel study published by Díaz-Gay et al in Nature. The findings demonstrated a substantial enrichment of colibactin-related...
Use of Statins in CLL/SLL
Statin use during targeted therapy treatment led to a 61% improvement in the risk of dying of cancer for patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), according to the results of a study published in Blood Advances. The investigators sought to determine the...
Use of Investigational Tool to Detect Advanced-Stage Invasive Cervical Cancer
At the 2025 Society of Gynecologic Oncology (SGO) Annual Meeting on Women’s Cancer, Kersten Rothnie, MBBS, a gynecologic oncology fellow at Northwell Health in New York City, shared study findings on an investigational tool on behalf of her colleagues.1 These results suggested the presence of...
Several Trials Show Clinical Activity With Osimertinib in Advanced EGFR-Mutant Non–Small Cell Lung Cancer
Updates from several clinical trials of the EGFR tyrosine kinase inhibitor osimertinib across stages and settings of EGFR-mutated non–small cell lung cancer (NSCLC) were presented at the European Lung Cancer Congress (ELCC) 2025. The updated results from the phase III LAURA trial were presented by ...
Polygenic Risk Score for Prostate Cancer Screening
In a U.K. study (BARCODE1) reported in The New England Journal of Medicine, McHugh et al found that screening for prostate cancer with a polygenic risk score was more accurate in diagnosis than screening with prostate-specific antigen (PSA) and magnetic resonance imaging (MRI). Study Details In...
Response to Immune Checkpoint Inhibitors Not Affected by Age
Older patients with a solid tumor responded with similar clinical outcomes to younger patients treated with immune checkpoint inhibitors, the results of a study published in Nature Communications showed. However, older patients did have divergent immune phenotypes compared with younger patients,...
Reduced Elective Dose in Definitive Radiotherapy for Head and Neck Squamous Cell Carcinoma
In a Dutch trial (UPGRADE-RT) reported in the Journal of Clinical Oncology, van den Bosch et al found that definitive radiotherapy with reduced-dose elective neck irradiation was safe and effective compared with standard-dose elective neck irradiation in patients with head and neck squamous cell...
Extended Follow-up of Belzutifan Treatment for von Hippel–Lindau Disease–Associated Renal Cell Carcinoma
In extended follow-up of the phase II LITESPARK-004 trial reported in The Lancet Oncology, Srinivasan et al found that use of the hypoxia-inducible factor-2α inhibitor belzutifan was associated with maintained benefit in patients with von Hippel–Lindau disease–associated renal cell carcinoma. The...
Medicare Claim Denials for Cancer-Related NGS Testing Show Uncertainty of Coverage
More than 20% of cancer-related claims for next-generation sequencing (NGS) from Medicare beneficiaries were denied between 2016 and 2021. Findings from a cohort study published in JAMA Network Open suggested that there is continued uncertainty about the boundaries of coverage for NGS, even with...
Therapy With a Tyrosine Kinase Inhibitor for EGFR-Variant Lung Adenocarcinoma: Lessons From Chronic Myeloid Leukemia?
There has been remarkable progress in treating EGFR-variant lung adenocarcinoma with tyrosine kinase inhibitors such as gefitinib, erlotinib, osimertinib, and afatinib. However, several important issues remain unresolved, including whether there remains a role for chemotherapy, who should receive a ...
Updated CAP Guideline Aims to Address Rising Rates of HPV-Associated Squamous Cell Carcinomas
The College of American Pathologists (CAP) updated its testing guideline to capture new research and emerging technologies to improve the diagnostic accuracy of human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinomas, according to a guideline update published by Lewis et al in...
Patient Support Found for AI Use as Second Reader of Mammograms
A survey study has shown cautious patient support for the use of artificial intelligence (AI) as a second reader in screening mammograms, according to results published in Radiology: Imaging Center. The study authors sought to determine the sentiments of patients regarding AI use in mammogram...
Some Patients With Advanced NSCLC Experience Durable Disease Control After Immunotherapy Discontinuation
Although immune checkpoint inhibitors (ICIs) have transformed the treatment landscape over the last decade for patients with non–small cell lung cancer (NSCLC), the agents can also stimulate uncontrolled immunity against normal tissues and organs, leading to a cascade of immune-related adverse...
How Does Medicaid Expansion Affect Access to Care in Patients With NSCLC?
A recent study published by Hooda et al in The Annals of Thoracic Surgery suggests that Medicaid expansion under the Affordable Care Act has significantly improved access to timely treatment and high-volume hospitals for patients with early-stage non–small cell lung cancer (NSCLC). These findings...
Dual Use of Cigarettes and E-Cigarettes on Par With Sole Cigarette Use in Terms of Toxic Exposure
Individuals who reported exclusive use of combustible cigarettes as well as those who reported dual use of both cigarettes and e-cigarettes showed similarly high toxicant exposure, according to the results of a study published in Nicotine & Tobacco Research. Both groups of smokers showed higher ...
Link Between CT Scans and Future Cancer Incidence?
At current use and radiation dose levels, computed tomography (CT) scans may eventually account for 5% of all cancers annually, according to a recent modeling study published by Smith-Bindman et al in JAMA Internal Medicine. The danger is greatest for infants, followed by children and...
Immunotherapy, Radiosurgery Combination and Risk of Radiation Necrosis in Patients With Cancer Who Have Brain Metastases
Patients with melanoma and lung cancer who have brain metastases may experience severe inflammatory reactions after receipt of immunotherapy drugs combined with radiation therapy, according to a recent study published by Vaios et al in JAMA Network Open. Study Methods and Results In this study,...
FDA Approves Bevacizumab Biosimilar
The U.S. Food and Drug Administration (FDA) has approved bevacizumab-nwgd (Jobevne), a biosimilar to bevacizumab (Avastin), for intravenous use. Bevacizumab-nwgd is a recombinant humanized monoclonal antibody and a vascular endothelial growth factor (VEGF) inhibitor that binds with VEGF and blocks...
Ideal Apixaban Dose for Cancer-Associated VTE
In the API-CAT trial—results of which were reported in The New England Journal of Medicine—Mahé et al found that use of reduced-dose apixaban was noninferior to full-dose apixaban in preventing recurrent venous thromboembolism (VTE) in patients with active cancer. Study Details In the double-blind...
Novel Strategy May Enhance Sensitivity, Accuracy of Monitoring Cancer in Blood Samples
A whole-genome sequencing–based, error-corrected method for detecting cancer from blood samples could be more sensitive and accurate in monitoring disease status posttreatment among patients with cancer compared with prior methods, according to a recent study published by Cheng et al in Nature...
Prostate Cancer: Biomarker Test May Predict GU Toxicity From SBRT
Researchers have developed, and now validated, a biomarker test to predict for genitourinary (GU) adverse events induced by stereotactic body radiotherapy (SBRT) in patients with prostate cancer, according to the results of a study published by Kishan et al in Clinical Cancer Research. The test,...
Crossing State Borders: Addressing Residential Barriers to Cancer Care
A high proportion of Medicare beneficiaries cross state borders to access cancer care, particularly patients residing in rural areas, according to a recent study published by Moen et al in JAMA Network Open. The findings have significant implications for telehealth policies and physician licensure, ...
Preclinical Study Finds FGFR2 Inhibition May Prevent Some KRAS-Expressing Pancreatic Cancers
Pancreatic ductal adenocarcinoma, the most common type of pancreatic cancer, is also among the most deadly, with an average 5-year survival rate of less than 10%. The malignancy is often preceded by precancerous lesions. Traditional treatments of the cancer, including chemotherapy, surgery, and...
